Idiopathic edema. Edema, unspecified
Conditions
Interventions
Intervention 1: Intervention group: For patients in the main group, empagliflozin 10 mg tablets manufactured by Abidi Pharmaceutical Company in Iran are prescribed. One empagliflozin tablet with 50 cc
Sponsors
Ahvaz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Patients over 18 years of age who refer due to generalized edema The patient does not take drugs that cause edema In the diagnostic investigations, there are no disorders, including kidney, heart, liver, thyroid, etc. There should be no justification and cause of generalized edema for the patient
Exclusion criteria
Exclusion criteria: Patients who do not want to cooperate and participate in the research Patients with diseases such as advanced renal failure, liver failure, chronic or recurrent UTI Patients with immune deficiency or diabetes Patients who use drugs that interfere with the intervention process
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The amount of edema. Timepoint: At the beginning of the study, 2, 6 and 12 weeks after starting the mentioned drug. Method of measurement: TANITA body analysis device. | — |
Secondary
| Measure | Time frame |
|---|---|
| The amount of physical activity in the International Physical Activity Questionnaire. Timepoint: before the intervention and then at the end of the second, sixth and twelfth weeks. Method of measurement: International Physical Activity Questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactShokouh Shayanpour
Ahvaz University of Medical Sciences
Outcome results
None listed